Gel-type autologous chondrocyte (Chondron™) implantation for treatment of articular cartilage defects of the knee

Autor: Choi, Nam-Yong; Kim, Byoung-Woo; Yeo, Woo-Jin; Kim, Haeng-Boo; Suh, Dong-Sam; Kim, Jin-Soo; Kim, Yoon-Sik; Seo, Yong-Ho; Cho, Jea-Yeong; Chun, Chung-Woo; Park, Hyun-Shin; Shetty, Asode; Kim, Seok-Jung
Sprache: Englisch
Veröffentlicht: 2010
Quelle: BioMed Central
Online Zugang: http://www.biomedcentral.com/1471-2474/11/103
http://www.biomedcentral.com/1471-2474/11/103
Erfassungsnummer: ftbiomed:oai:biomedcentral.com:1471-2474-11-103

Zusammenfassung

Abstract Background Gel-type autologous chondrocyte (Chondron™) implantations have been used for several years without using periosteum or membrane. This study involves evaluations of the clinical results of Chondron™ at many clinical centers at various time points during the postoperative patient follow-up. Methods Data from 98 patients with articular cartilage injury of the knee joint and who underwent Chondron™ implantation at ten Korean hospitals between January 2005 and November 2008, were included and were divided into two groups based on the patient follow-up period, i.e. 13~24-month follow-up and greater than 25-month follow-up. The telephone Knee Society Score obtained during telephone interviews with patients, was used as the evaluation tool. Results On the tKSS-A (telephone Knee Society Score-A), the score improved from 43.52 ± 20.20 to 89.71 ± 13.69 (P < 0.05), and on the tKSS-B (telephone Knee Society Score-B), the score improved from 50.66 ± 20.05 to 89.38 ± 15.76 (P < 0.05). The total improvement was from 94.18 ± 31.43 to 179.10 ± 24.69 (P < 0.05). Conclusion Gel-type autologous chondrocyte implantation for chondral knee defects appears to be a safe and effective method for both decreasing pain and improving knee function.